Anti-KLF6, Splice Variant 1 [9A2] Antibody
This mouse IgG2a monoclonal antibody was generated against recombinant human KLF6 splice variant 1 (SV1), and is specific for human KLF6 SV1.
Krueppel-like factor 6 (KLF6), also known as GBF, ZF9, BCD1, CPBP, PAC1, ST12, and COPEB, is a protein that in humans is encoded by the KLF6 gene. It is a tumor suppressor gene and encodes a nuclear protein that has three zinc fingers at the end of its C-terminal domain, a serine/threonine-rich central region, and an acidic domain lying within the N-terminal region. The zinc fingers of this protein are responsible for the specific DNA binding with the guanine-rich core promoter elements. The central region is involved in activation or posttranslational regulatory pathways, and the acidic N-terminal domain is proposed to play an important role in the process of transcriptional activation.
KLF6 is capable of activating transcription approximately 4-fold either on homologous or heterologous promoters. Although wild-type KLF6 acts as a tumor suppressor, KLF6 splice variant 1 (sv1) has the opposite effect on cell proliferation, colony formation and invasion. Inhibition of KLF6 sv1 with short interfering RNA reduces tumor cell growth by 50% and decreases the number of growth and angiogenesis-related genes.
From the laboratory of Goutham Narla, MD, PhD, Icahn School of Medicine at Mount Sinai.
Part of The Investigator's Annexe program.
This mouse IgG2a monoclonal antibody was generated against recombinant human KLF6 splice variant 1 (SV1), and is specific for human KLF6 SV1.
Krueppel-like factor 6 (KLF6), also known as GBF, ZF9, BCD1, CPBP, PAC1, ST12, and COPEB, is a protein that in humans is encoded by the KLF6 gene. It is a tumor suppressor gene and encodes a nuclear protein that has three zinc fingers at the end of its C-terminal domain, a serine/threonine-rich central region, and an acidic domain lying within the N-terminal region. The zinc fingers of this protein are responsible for the specific DNA binding with the guanine-rich core promoter elements. The central region is involved in activation or posttranslational regulatory pathways, and the acidic N-terminal domain is proposed to play an important role in the process of transcriptional activation.
KLF6 is capable of activating transcription approximately 4-fold either on homologous or heterologous promoters. Although wild-type KLF6 acts as a tumor suppressor, KLF6 splice variant 1 (sv1) has the opposite effect on cell proliferation, colony formation and invasion. Inhibition of KLF6 sv1 with short interfering RNA reduces tumor cell growth by 50% and decreases the number of growth and angiogenesis-related genes.
From the laboratory of Goutham Narla, MD, PhD, Icahn School of Medicine at Mount Sinai.
Part of The Investigator's Annexe program.
| Product Type: | Antibody |
| Name: | Anti KLF6 monoclonal antibody (9A2) |
| Accession ID: | Q99612 |
| Host: | Mouse |
| Isotype: | IgG2a |
| Clonality: | Monoclonal |
| Clone Name: | 9A2 |
| Specificity: | This antibody recognizes Human KLF6 splice variant 1 (sv1) |
| Immunogen: | Human KLF6 splice variant 1 recombinant protein |
| Format: | Liquid |
| Purification Method: | Protein G purified |
| Buffer: | PBS, 0.05% (w/v) Sodium Azide |
| Tested Applications: | IHC, WB, ELISA |
| Concentration: | 1 mg/mL |
| Amount: | 100uL |
| Storage: | Store at 4C |
| Shipped: | Cold packs |
|
|
| Increased KLF6-SV1 expression in metastatic PCa. Western blot analysis using a KLF6-SV1specific monoclonal antibody. Transfected KLF6-SV1 and transfected wild-type KLF6 controls were run on the same gel but were noncontiguous. Tubulin was used as the loading control for all lanes. Adapted from: Narla, G., et al., KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 118:27112721 (2008). |
- Tchirkov et al. Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin Chem lab Med, 48, 1167, 2010.
- Sangodkar et al. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer, 66, 292, 2009.
- Narla, G., et al., KLF6-SV1 overexpression accelerateshuman and mouse prostate cancerprogression and metastasis. J. Clin. Invest. 118:27112721 (2008).
- DiFeo et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.Cancer Res, 68, 965, 2008.
If you publish research with this product, please let us know so we can cite your paper.
